Core Insights - The company, Panlong Pharmaceutical, plans to purchase 147 furnished apartments for employee accommodation, with a total transaction price exceeding its net profit for the first half of the year [1][2]. Financial Performance - For the first half of 2025, Panlong Pharmaceutical reported a revenue of 574 million yuan, a year-on-year increase of 26.06%, and a net profit of 60.14 million yuan, a year-on-year increase of 0.81% [1][4]. - The company also achieved a net profit excluding non-recurring items of 52.86 million yuan, reflecting a year-on-year growth of 4.19% [4]. Employee Welfare Initiatives - The acquisition of the "Bicuiyuan" project is aimed at improving the living conditions of employees and ensuring a stable workforce, which is deemed necessary and reasonable for the company's operations [3]. - The company emphasizes its commitment to employee welfare, stating that it aims to create a "spiritual home" for employees and ensure they lead good lives [1][5]. Company Background - Panlong Pharmaceutical was established in 1997 and listed on the Shenzhen Stock Exchange in November 2017, focusing on standardized planting of medicinal materials, drug production, research and development, sales, and pharmaceutical logistics [4]. - As of the end of 2024, the company had a total of 933 employees [4].

南财智讯9月20日电，盘龙药业公告，公司于2025年9月19日召开第五届董事会第一次会议，选举谢晓林 为董事长，审议通过了第五届董事会各专门委员会的组成，聘任张德柱为副总裁并代行总裁职务，吴杰 为董事会秘书，祝凤鸣为财务总监，孟重和黄继林为副总裁，赵晓妮为证券事务代表。上述人员均具备 相应任职资格，任期自第五届董事会第一次会议审议通过之日起至第五届董事会任期届满之日止。 ...

Group 1 - The core viewpoint of the article is that Panlong Pharmaceutical held its first board meeting of the fifth session on September 19, 2025, to discuss the appointment of the board secretary and other related documents [1] - For the first half of 2025, Panlong Pharmaceutical's revenue composition was as follows: pharmaceutical manufacturing and sales accounted for 99.34%, other products accounted for 0.52%, and health products accounted for 0.14% [1] - As of the report date, Panlong Pharmaceutical's market capitalization was 3.2 billion yuan [1]

证券代码：002864 证券简称：盘龙药业 公告编号：2025-046 陕西盘龙药业集团股份有限公司 关于购买资产暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关联交易概述 陕西盘龙药业集团股份有限公司（以下简称"公司"）为全力支持西渝高铁 项目建设，已按计划完成原有职工宿舍楼的拆除工作。为妥善解决生产基地员工 的住宿需求，切实改善员工生活与休息条件，为其营造更加安全、舒适的生活和 工作环境，公司现拟购置陕西嘉兴房地产开发有限公司（以下简称"嘉兴地产"） 开发的"碧翠苑"项目 5 号楼，作为专门的生产基地员工公寓。 本次交易对方嘉兴地产为公司控股股东、实际控制人谢晓林先生直接控股的 企业。根据《深圳证券交易所股票上市规则》的规定，本次交易构成关联交易。 公司于 2025 年 9 月 19 日召开第五届董事会第一次会议审议通过了《关于公 司购买资产暨关联交易的议案》，关联董事谢晓林、谢晓锋先生回避表决，本次 关联交易事项在提交董事会审议前已经公司 2025 年第二次独立董事专门会议审 议通过。本次交易金额及公司连续十二个月内与关联方累计已 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于 2025 年 9 月 19 日召开了第五届董事会第一次会议，分别审议通过了选举公司第五届董事会董事 长、各专门委员会委员、聘任高级管理人员及证券事务代表等相关议案。现将具 体情况公告如下： 一、第五届董事会董事长选举情况 经与会董事审议，同意选举谢晓林先生为公司第五届董事会董事长，任期三 年，自第五届董事会第一次会议审议通过之日起至第五届董事会任期届满之日止。 二、公司第五届董事会各专门委员会组成情况 第五届董事会专门委员会组成情况如下： 证券代码：002864 证券简称：盘龙药业 公告编号：2025-045 陕西盘龙药业集团股份有限公司 关于选举董事长、专门委员会委员、聘任高级管理人员及证券 事务代表的公告 | 序号 | 专门委员会名称 | 主任委员 | 委员 | | --- | --- | --- | --- | | 1 | 审计委员会 | 王鹏 | 王鹏、王满仓、朱文锋 | | 2 | 可持续战略发展委员会 | 谢晓林 | 谢晓林、张德柱、牛晓峰 | | ...

证券代码：002864 证券简称：盘龙药业 公告编号：2025-044 陕西盘龙药业集团股份有限公司 第五届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 陕西盘龙药业集团股份有限公司（以下简称"公司"）第五届董事会第一次 会议通知于 2025 年 9 月 16 日以邮件方式向各位董事、独立董事发出。本次会议 于 2025 年 9 月 19 日下午 14:00 在西安市灞桥区现代纺织产业园灞柳二路 2801 号陕西盘龙医药股份有限公司二楼会议室采取现场结合通讯方式召开。会议应出 席董事 9 名，实际出席董事 9 名。经与会董事一致推选，本次会议由谢晓林先生 主持。公司全体高级管理人员候选人列席了本次会议。 会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律、行政 法规、部门规章、规范性文件及《陕西盘龙药业集团股份有限公司章程》的有关 规定。 二、董事会会议审议情况 经与会董事认真审议，形成以下决议： 案》 董事会同意选举以下人员为第五届董事会各专门委员会委员，任期三年，自 本次董事会审议通过之日起至本 ...

中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 6161070005202500164 | | | --- | --- | --- | | 合同编号: | ZDXP-2025-175 | | | 报告类型: | 非法定评估业务资产评估报告 | | | 报告文号: | 陕正德信评报字(2025) 145号 | | | 报告名称: | 陕西盘龙药业集团股份有限公司拟购买资产所涉及的碧翠苑5号楼 项目资产评估报告 | | | 评估结论: | 67,791,500.00元 | | | 评估报告日: | 2025年09月12日 | | | 评估机构名称: | 陕西正德信资产评估有限公司 | | | 签名人员: | 郭凯 (资产评估师) | 正式会员 编号: 61200025 | | | 赵养峰 (资产评估师) | 正式会员 编号: 61200038 | | | 郭凯、赵养峰已实名认可 | | (可扫描二维码查询备案业务信息) 说明:报告备案回执仅证明此报告已在业务报备管理系统进行了备案,不作为 协会对该报告认证、认可的依据,也不作为资产评估机构及其签字资产评估专 业人员免除相关法律责任的依据。 备案回执 ...

中药配方颗粒业务尚处起步，稳步推进拓展 盘龙药业于2025年9月18日通过线上交流会的形式，接受了华福证券、华创证券、农银基金等3家机构的 调研。公司董事长谢晓林先生、证券事务代表赵晓妮及投资者关系管理经理梁馨方参与接待，就中药配 方颗粒业务、中药创新药进展、分红政策及基层市场开发策略等投资者关心的问题进行了交流。 在谈及中药配方颗粒业务何时能成为第二增长曲线时，盘龙药业表示，已于2024年年末完成中药配方颗 粒智能化生产线建设，并成立业务发展中心。截至目前，累计完成研发备案上市品种数达310个，在18 个省份完成挂网备案。该业务现阶段以陕西省为中心，逐步向外拓展业务覆盖范围。 创新药研发多点开花，梯度布局推进 对于中药创新药的进展，公司透露，中药改良型新药PL JT004已进入CDE临床受理阶段；化学仿制药 PL-JT001完成BE试验待报产；化学仿制药（PLJT - 002/003）年内启动IND申报；1.1类中药创新药 PLZY - 001/PL - XP013/PL - XP012分阶段推进临床前及II期工作。公司通过梯度化管线布局推 动"21355"大品种培育目标，构建立体产品生态，提升产品核心竞争 ...

Group 1: Business Development and Growth Strategies - The company has completed the construction of an intelligent production line for traditional Chinese medicine formula granules by the end of 2024, with 310 varieties registered and listed in 18 provinces [2][3] - The company is focusing on expanding its traditional Chinese medicine formula granules business, starting from Shaanxi province and gradually extending its coverage [2][3] - The company is advancing its innovative drug development strategy, with several products in various stages of clinical trials and regulatory submissions [3][4] Group 2: Financial Performance and Shareholder Returns - The company emphasizes enhancing shareholder returns through increased dividend ratios and frequency, with a three-year dividend return plan approved for 2025-2027 [3][4] - The management is committed to balancing short-term shareholder returns with long-term company growth, focusing on management innovation and optimizing cost structures to support dividends [3][4] Group 3: Market Expansion and Marketing Strategies - The company has established a comprehensive marketing management system to expand its presence in grassroots markets while maintaining high coverage in tiered hospitals [4][5] - The product distribution has reached over 20,000 grassroots medical institutions and more than 30,000 retail pharmacies, creating a dual-driven model of medical and retail [4][5] - The company is actively developing an "Internet + Medicine" strategy, forming a professional digital marketing team and collaborating with leading e-commerce platforms [5]

Core Viewpoint - The Chinese medicine sector is experiencing a mixed performance, with the leading Chinese medicine ETF (560080) showing resilience despite market fluctuations, attracting significant capital inflows and demonstrating strong growth potential in the context of regulatory changes and industry innovation efforts [1][4][6]. Market Performance - The Chinese medicine ETF (560080) recorded a slight decline but maintained a premium throughout the day, with a trading volume exceeding 71 million yuan. Over the past 10 days, it has seen net inflows on 9 occasions, totaling over 150 million yuan, and its latest scale has surpassed 2.4 billion yuan, leading its peers [1][4]. - Major components of the ETF index mostly experienced pullbacks, with Renhe Pharmaceutical declining over 1%, while Panlong Pharmaceutical rose over 1% [3][5]. Financing and Investment Trends - Leveraged funds are increasingly utilizing the ETF to invest in the high-value Chinese medicine consumer sector, with the latest financing balance approaching 80 million yuan and a financing buy-in amount exceeding 12 million yuan as of September 16, 2025 [4]. - The Chinese medicine industry is viewed as having stable cash flow and high dividends, with companies like Huaren Sanjiu and Jiangzhong Pharmaceutical showing strong performance in their incentive plans, which are expected to drive new growth [7][8]. Regulatory Developments - The National Medical Products Administration has announced new regulations for Chinese medicine production supervision, effective March 1, 2026, emphasizing quality control throughout the entire production process [5]. Innovation and Growth Strategies - Chinese medicine companies are actively pursuing innovation and transformation into chemical and biological pharmaceuticals through self-research, mergers and acquisitions, and strategic partnerships, aiming to create a second growth curve [6]. - The industry is expected to see improved performance in the second half of 2025, driven by reduced cost pressures from declining raw material prices and enhanced operational efficiencies [7][9]. Dividend and Profitability Insights - A significant number of central state-owned enterprises in the Chinese medicine sector are projected to have dividend yields exceeding 3% in 2024, with Jiangzhong Pharmaceutical and Dong'e Ejiao leading in dividend rates [8][9]. - Despite facing growth pressures in the first half of 2025, many companies have managed to achieve positive growth in net profit through quality improvement and efficiency enhancement strategies [9]. Market Sentiment and Future Outlook - The Chinese medicine index is gradually recovering, with institutional holdings remaining light. The sector is expected to attract more capital as it combines attributes of new consumer demand and pharmaceutical needs [10][12].